meRfi®-GM
Head & Neck cancer
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Worldwide, head and neck carcinomas account for 5% of all malignancies. Unfortunately, two-thirds of patients relapse after initial multimodal therapy. Until early 2010, the median overall survival (OS) of metastatic patients was approximately 10 months.
Head and neck cancer is the seventh most common type of cancer worldwide, comprising a diverse group of tumors that affect the upper aerodigestive tract. Although many different histologies exist, the most common type is Head & Neck squamous cell carcinoma (HNSCC)
Head and neck cancer includes tumors that develop in the:
- Mouth
- Throat
- Nose
- Salivary glands
- Oral regions
- Other area…
References (Sources)
- A retrospective analysis of the outcome of pts with recurrent and/or metastatic HNSCC refractory to a platinum-based chemotherapy
- Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma
- Editorial: Head and neck cancers: new perspectives in prevention and treatment
- Integrin alpha 7 correlates with worse clinical features and prognosis, and its knockdown inhibits cell proliferation and stemness in tongue squamous cell carcinoma
- Open the Gates for Treatment De-Intensification in Head and Neck Cancer
- Randomized clinical study on intratumoral BCG-cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck region
- The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma